Xention Receives Wellcome Trust Award for Atrial Fibrillation Programme
News Jul 07, 2009
XENTION LTD, the Cambridge-based biopharmaceutical company specializing in the discovery and development of ion channel-modulating drugs, announced that it had received a substantial award from the Wellcome Trust to support pioneering work on an exciting target for atrial fibrillation.
The award, made under Wellcome’s Seeding Drug Discovery initiative, will provide up to £3 million to fund Xention’s IKACh programme over a period of three years. IKACh is the acetylcholine-activated potassium current encoded by the Kir3.1/3.4 ion channel genes and is an emerging ion channel target for the development of new therapeutics for atrial fibrillation, an area in which Xention has already broad expertise.
IKACh is expressed only in the atria, and inhibition of IKACh is expected to maintain sinus rhythm in patients who have experienced episodes of atrial fibrillation. Using the funding provided by Wellcome, Xention will develop small molecule, orally active inhibitors of IKACh for assessment in in vivo models and subsequent progression into clinical development.
This approach is of great interest to clinicians in a therapeutic area that is currently underserved with clinically effective, well-tolerated, medicines. Xention’s IKACh programme will complement its existing Kv1.5 programme, the most advanced compound from which is currently in clinical development.
“We are very pleased to have received this prestigious award,” commented Tim Brears, Xention’s Chief Executive. “We look forward to working with the Wellcome Trust over the coming years to develop new therapeutics in this area of substantial unmet medical need.”
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.